Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Argus Health
US Department of Justice

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,148,207

« Back to Dashboard

Which drugs does patent 7,148,207 protect, and when does it expire?

Patent 7,148,207 protects OFORTA and is included in one NDA.

This patent has thirty-six patent family members in thirty countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 7,148,207

Title:Oral fludara of high-purity formulation with quick release of active ingredient
Abstract:This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.
Inventor(s): Heil; Wolfgang (Stelle, DE), Tistam; Ulf (Wezembeek Oppem, BE), Lipp; Ralph (Berlin, DE), Tack; Johannes-Wilhelm (Berlin, DE)
Assignee: Schering Aktiengesellschaft (Berlin, DE)
Application Number:10/324,141
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Sanofi Aventis UsOFORTAfludarabine phosphateTABLET;ORAL022273-001Dec 18, 2008DISCNNoNo► Subscribe► Subscribe► SubscribeYTREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,148,207

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany101 64 510Dec 20, 2001

International Patent Family for Patent: 7,148,207

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI255187► Subscribe
Ukraine78741► Subscribe
Taiwan200305428► Subscribe
Russian Federation2318496► Subscribe
Saudi Arabia1594► Subscribe
Russian Federation2004122479► Subscribe
Serbia50398► Subscribe
Serbia53304► Subscribe
Peru06392003► Subscribe
Poland370792► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: